We develop a combined treatment with a statin and an anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody that significantly reduces the severity of PF, more effectively than either treatment alone, by increasing LDLR and lowering LDL in mice. This evidence concerns the gene PCSK9 and pemphigus foliaceus.